
News|Articles|January 5, 2024
Cell and Gene Therapies – When Speed Matters
Author(s)Eurofins
Eurofins acknowledges the significance of Cell and Gene Therapies, particularly Autologous Cell Therapies , in the healthcare industry. Recognizing the urgency associated with short shelf-life products, Eurofins BioPharma Product Testing has developed a comprehensive set of services to address the need for swift and reliable testing. This suite of services positions Eurofins as a one-stop-shop for rapid and facility testing requirements. Clients can benefit from guaranteed short turnaround times while maintaining the highest quality standards for tests crucial in ensuring the safety of Cell and Gene Therapies for patient administration.
Trending on Pharmaceutical Technology
1
Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement
2
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
3
Technology Transfer: Success Drivers and Obstacles Explained
4
Data Aggregation Drives AI's Impact on Clinical Supply Chains
5
